MAT2501 Phase 1 Data Look Good, Shares Look Attractive
Wednesday, March 29, 2017 10:09 AM EDT
Matinas Biopharma's stock is cheap and I can easily see Matinas getting taken out at much higher levels - like most anti-infectant companies do - perhaps after the pipeline matures a bit.
In this article: MTNB